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Summary 
This study investigated whether endothelin (ET)-1-induced 
increase in myocardial distensibility is preserved in heart failure 
(HF) and whether it is modulated by nitric oxide (NO) and 
prostaglandins. New Zealand white rabbits were treated with 
doxorubicin (1 mg/kg, intravenously twice a week for 8 weeks, 
DOX-HF group) or saline (control group). Effects of ET-1 (0.1, 1, 
10 nM) were tested in papillary muscles from the DOX-HF group 
and a control group in the presence of: i) intact endocardial 
endothelium (EE); ii) damaged EE; iii) NG-nitro-L-arginine  
(L-NNA; NO synthase inhibitor), and iv) indomethacin (INDO; 
cyclooxygenase inhibitor). In the presence of an intact EE, ET-1 
promoted concentration-dependent positive inotropic and 
lusitropic effects that were maintained after damaging the EE, in 
the presence of L-NNA or INDO and in the DOX-HF Group. ET-1 
reduced resting tension at the end of the isometric twitch 
(increased diastolic distensibility) by 3.2±1.3 %, 6.0±1.6 % and 
8.8±2.7 % (at 0.1, 1 and 10 nM, respectively), in muscles with 
intact EE, effect that was completely abolished after damaging 
EE, in the presence of L-NNA or INDO or in the DOX-HF Group. 
This study demonstrated that the increase in myocardial 
distensibility induced by ET-1 is absent in HF and is dependent of 
NO and prostaglandin release.  
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Introduction 
 
The discovery of endothelin (ET)-1, one of the 
most potent endogenous vasoconstrictor peptides, by 
Yanagisawa et al. (1988) represented a landmark in the 
field of cardiovascular research. Since its discovery, a 
great deal of effort has been exerted in gaining a better 
understanding of the key roles (developmental, 
physiological, and pathological) played by this peptide, 
particularly with regard to the cardiovascular system, 
where the components of the endothelin system are 
widely expressed, namely in vascular and endocardial 
endothelium, smooth muscle cells and cardiomyocytes 
(Brunner et al. 2006). ET-1 acts in two main subtypes of 
G-protein coupled receptors (ETA and ETB) and has 
mainly local autocrine and paracrine actions, since it is 
released abluminally and has a short half-life. In heart 
failure (HF), the plasma, salivary and tissue levels of  
ET-1 are increased and are positively related to the stage 
of the disease and negatively to its prognosis (Attina et 
al. 2005). ETA receptors mediate vasoconstriction, 
mitogenesis and positive inotropism. ETB receptor 
activation promotes mainly vasodilatation and has growth 
inhibitory effects associated with apoptosis. These 
receptors also mediate the pulmonary clearance of 
circulating ET-1 and the reuptake of ET-1 by endothelial 
cells. In the heart (Leite-Moreira and Bras-Silva 2004) 
and in the vasculature (Endoh et al. 1998), it is possible 
to further subclassify the ETB receptors into ETB1 
receptors, located on the vascular and endocardial 
endothelium and responsible for vasodilatation and 
negative inotropism, and ETB2 receptors, located on 
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vascular muscular and myocardial cells and responsible 
for vasoconstriction and positive inotropism, 
respectively. 
Unlike the well-known role of chronically 
elevated ET-1 levels in progression of cardiac fibrosis 
and ventricular remodeling, the acute diastolic effects of 
ET-1 in the failing myocardium remain less explored. We 
have previously reported, in healthy animals that ET-1 
acutely decreases myocardial stiffness under the 
conditions of cardiac overload (Leite-Moreira et al. 
2003). Although mediated by ETA receptor stimulation 
(Leite-Moreira et al. 2003), this effect requires an intact 
endocardial endothelium (EE) and active endothelial 
ETB1 receptors (Bras-Silva and Leite-Moreira 2006). This 
is in agreement with the growing experimental evidence 
for a paracrine regulation of cardiac systolic and diastolic 
performance by endocardial endothelial cells that is 
analogous to vascular endothelial control of vascular tone 
(Brutsaert 2003). Until recently, a major limitation for the 
evaluation of EE dysfunction was the non-existence of a 
functional marker, such as acetylcholine for the vascular 
endothelium. We have recently gathered evidence that the 
response to selective ETB receptor stimulation might be 
used as such a marker. Using this approach we 
documented endocardial endothelial dysfunction in an 
experimental model of HF, the so-called doxorubicin-
induced HF (Bras-Silva et al. 2006).  
In this context, the present study was conducted 
in order to investigate whether the diastolic effects of ET-
1 were preserved in HF, and whether they are dependent 
on two of the most important endothelial mediators, nitric 
oxide and prostaglandins.  
  
Methods 
 
The investigation conforms to the Guide for the 
Care and Use of Laboratory Animals published by the US 
National Institutes of Health (NIH Publication Nº 85-23, 
Revised 1996). The study was performed on New-
Zealand White rabbits (Oryctolagus cuniculus; n=37;  
1.8-3.0 kg). 
 
Heart failure model 
A well documented regimen was used for the 
induction of HF due to doxorubicin toxicity (DOX-HF) 
(Arnolda et al. 1985). Adult male New Zealand White 
rabbits received doxorubicin (DOX) via a marginal ear 
vein by bolus injection (1 mg/kg) twice weekly for 
8 weeks (n=16) followed by a washout period of 1 week. 
Control rabbits (n=21) received the vehicle (0.9 % saline) 
in equivolumetric doses over the same period. 
Echocardiographic evaluation of all the animals was used 
to monitor left ventricular dilatation and dysfunction 
during the development of HF. In two subgroups of 
control and DOX-HF hemodynamic evaluation was also 
performed. The experimental protocols were carried out 
in an isolated papillary muscle model.  
 
Echocardiographic evaluation 
All animals were evaluated by echocardiography 
at the beginning and every two weeks during the 
administration of DOX or vehicle. Echocardiographic 
examination was performed as previously described 
(Fontes-Sousa et al. 2006). Briefly, the rabbits were 
lightly anesthetized with an intramuscular combination of 
ketamine hydrochloride (2 mg/kg) and medetomidine 
hydrochloride (0.15 mg/kg), being allowed to breath 
spontaneously. The animals were placed prone on a table 
with an area removed so that the ultrasound probe could 
be brought from below and placed on a shaved area of the 
anterior chest wall. The echocardiograms were obtained 
using a 7.5 MHz transducer (Vivid 3 General Electrics 
echocardiograph, Portugal) and the examination was 
performed from the right parasternal short-axis view. 
Two-dimensional guided M-mode tracings were made 
just below the mitral valve at the level of the papillary 
muscles for measurements of the left ventricular internal 
diameter and the left ventricular wall was free in diastole 
and systole. Three representative cycles were measured 
and averaged for each rabbit at each time point. Analyzed 
parameters were: heart rate, anterior and posterior end-
diastolic and end-systolic wall thickness, left ventricular 
end-systolic and end-diastolic diameters (ESD and EDD, 
respectively), fractional shortening (FS) [FS=(EDD-
ESD)/EDD]. 
 
Hemodynamic assessment 
The instrumentation of the animals for 
hemodynamic studies was performed one week after the 
last administration of the vehicle (n=6) or DOX (n=9), 
respectively, as previously described (Leite-Moreira et al. 
1999, Leite-Moreira and Correia-Pinto 2001). In 
summary, animals were premedicated with ketamine 
hydrochloride (50 mg/kg i.m.) and xylazine 
hydrochloride (5 mg/kg i.m.). An auricular vein was 
cannulated, and a prewarmed solution containing 20 mM 
KCl and 40 mM NaHCO3 in 500 ml of 0.9 % NaCl was 
administered to compensate for perioperative fluid losses. 
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A tracheostomy was performed, and mechanical 
ventilation was initiated (Harvard Small Animal 
Ventilator, model 683), delivering oxygen-enriched air. 
Respiratory rate and tidal volume were adjusted to keep 
arterial blood gases and pH within physiological limits. 
Anesthesia was maintained with ketamine hydrochloride 
(33 ml/kg/h i.m.) and pentobarbital sodium (12.5 mg/kg 
i.v. before opening the chest, and then 2.5 mg/kg i.v. as 
needed). A 20-gauge catheter was inserted into the right 
femoral artery and connected to a pressure transducer to 
monitor heart rate and arterial pressure, and to obtain 
samples for blood gas analysis. The heart was exposed by 
a median sternotomy, and the pericardium was widely 
opened. Transient aortic constrictions were performed by 
abruptly occluding the aorta with a silk suture placed 
around the ascending aorta during the diastole separating 
two heartbeats. This was achieved by pushing a plastic 
tube against the aorta with one hand while pulling the silk 
suture with the other hand. Aortic constriction was 
quickly released to avoid neurohumoral reflex changes in 
cardiac function (Leite-Moreira et al. 1999, Leite-
Moreira and Correia-Pinto 2001, Correia-Pinto et al. 
2006). Peak systolic pressure of isovolumetric heartbeats, 
which can be obtained with aortic occlusions, is a 
sensitive index of left ventricular contractility. A 3-F 
high-fidelity micro-manometer (SPR-524, Millar 
Instruments, Houston, TX, U.S.A.) was inserted through 
an apical puncture wound into the left ventricular (LV) 
cavity, positioned at the midventricular level, and secured 
in place with a purse-string suture to measure LV 
pressure. The manometer was calibrated against a 
mercury column and zeroed after stabilization for 30 min 
in a water bath at body temperature. A limb 
electrocardiogram (DII) was recorded throughout.  
After complete instrumentation, we allowed the 
animal preparation to stabilize for 30 min before the 
beginning of the experimental protocol. Recordings were 
made with respiration suspended at the end of expiration.  
Parameters were converted on-line to digital data 
with a sampling frequency of 500 Hz. LV pressures were 
measured at end diastole and peak systole. Peak rates of 
LV pressure rise (dP/dtmax) and pressure fall (dP/dtmin) 
were also measured. The relaxation rate was estimated 
with the time constant τ by fitting the isovolumetric 
pressure fall to a monoexponential function.  
Anesthetics ketamine hydrochloride (Imalgene 
1000®), medetomidine hydrochloride (Domitor®) and 
xylazine hydrochloride (Rompum®) were obtained from 
Merial Portuguesa – Saúde Animal, Pfizer Saúde Animal, 
and Bayer, Portugal, respectively. 
 
Papillary muscle studies 
The study was performed in isolated right 
papillary muscles from the control (n=41) and DOX-HF 
(n=15) groups one week after the last drug or saline 
administration. Rabbits were anesthetized with 
intravenous pentobarbital sodium (25 mg/kg). A left 
thoracotomy was performed and beating hearts were 
quickly excised and immersed in modified Krebs-Ringer 
(KR) solution (composition in mmol/l: NaCl 98; KCl 4.7; 
MgSO4 2.4; KH2PO4 1.2; glucose 4.5; CaCl2 1.8; 
NaHCO3 17; C3H3NaO3 15; CH3COONa 5; atenolol 0.02) 
at 35 ºC with cardioplegic 2,3-butanedione monoxime 
(BDM; 3 %) and 5 % of newborn calf serum and gassed 
with 95 % O2/5 % CO2, to obtain pH between 7.38-7.42. 
After dissection, papillary muscles (length: 
4.2±0.3 mm; weight: 2.9±0.3 mg; preload: 4.3±0.3 mN) 
were mounted vertically in a 10 ml plexi glass organ bath 
containing the above-described KR solution and attached 
to an electromagnetic length-tension transducer 
(University of Antwerp, Belgium). Preload was estimated 
according to muscle dimensions and the electrical 
stimulus (0.6 Hz) was set at 10 % above threshold. 
Twenty minutes later, bathing solutions were replaced by 
corresponding KR solutions without BDM. During the 
next two hours, muscles were stabilized. Bathing 
solutions were then replaced by corresponding KR 
solutions without calf serum and maximum physiological 
length (Lmax) was calculated. Protocols were initiated 
after obtaining two similar isotonic and isometric control 
twitches separated by a 10 min interval. 
 
Experimental protocols 
In a set of papillary muscles from control (n=8) 
and DOX-HF (n=7) groups, isometric contractility-
frequency relationships were obtained by plotting 
maximum velocity of tension rise against frequency of 
contraction. In summary, after an initial period of 
contraction at 0.6 Hz, the frequency of stimulation was 
stepped up at 3-min intervals to 1 Hz, 2 Hz, 3 Hz and 4 Hz. 
Myocardial effects of increasing concentrations 
of ET-1 (0.1, 1, and 10 nM) were studied in rabbit 
papillary muscles from: i) Control Group with intact 
endocardial endothelium (EE) (n=9); ii) Control Group 
with damaged EE (n=9); iii) Control Group in the 
presence NG-nitro-L-arginine (L-NNA; nitric oxide 
synthase inhibitor, 1 µM, n=8); iv) Control Group in the 
presence of indomethacin (INDO; cyclooxygenase 
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inhibitor, 1 µM, n=7) and (v) DOX-HF Group (n=8). 
The concentrations of ET-1 were selected on the 
basis of several studies showing that its physiological 
effects on contraction and distensibility of myocardial 
tissue preparations or whole heart preparations are 
exerted by concentrations in the nanomolar range (Shah 
et al. 1989, Firth et al. 1990, Leite-Moreira et al. 2003, 
Bras-Silva and Leite-Moreira 2006). 
EE was damaged by briefly (1 s) exposing the 
isolated papillary muscle to a weak solution (0.5 %) of 
the detergent Triton X-100 (Brutsaert et al. 1988, Leite-
Moreira and Bras-Silva 2004). 
Chemicals were obtained from Sigma Chemical 
Company (St. Louis, MO). 
 
Data analysis 
Isotonic and isometric twitches were recorded 
and analyzed. Selected parameters include: resting 
tension (RT) at the beginning (RTbeg, mN/mm2) and at the 
end (RTend, mN/mm2) of the twitch; active tension (AT, 
mN/mm2); maximum velocity of tension rise (dT/dtmax, 
mN/mm2/s); maximum velocity of tension decline 
(dT/dtmin, mN/mm2/s); peak isotonic shortening (PS, 
%Lmax); maximum velocity of shortening (dL/dtmax, 
Lmax/s), maximum velocity of lengthening (dL/dtmin, 
Lmax/s) and time to half relaxation (tHR, ms).  
When a pharmacological inhibitor (L-NNA or 
INDO) was used, the term baseline refers to the condition 
in the presence of those inhibitors before the addition of 
ET-1. 
In the various protocols, results are given as the 
percentage change from baseline. For the parameters that 
are expressed as negative values (e.g. dT/dtmin) such 
percentage change refers to the absolute values. 
 
Statistical methods 
Values are means ± S.E.M. Baseline 
performance of papillary muscles from control and DOX-
treated rabbits were compared with an unpaired t-test. 
Effects of increasing concentrations of ET-1 and of 
increasing stimulation frequencies on papillary muscles 
from control and DOX-treated rabbits were analyzed with 
a repeated-measures two-way ANOVA. Echocardio-
graphic data of DOX-treated animals at the beginning and 
at the end of the study were compared with a paired t test. 
Hemodynamic measurements at baseline and after 
treatment with DOX or saline were analyzed with a 
repeated-measures two-way ANOVA. When significant 
differences were detected, the Student-Newman-Keuls 
test was selected to perform multiple comparisons. 
Differences were considered to be significant when 
P<0.05. 
 
Results 
 
Cardiac hemodynamics and echocardiography 
The hemodynamic features of the experimental 
groups are summarized in Table 1. In comparison with 
the control group, the DOX-HF group presented a lower 
systolic pressure, dP/dtmax and peak systolic isovolumetric 
pressure. The left ventricular filling pressure, as estimated 
by left ventricular end-diastolic pressure, was increased 
in DOX-HF, whereas the dP/dtmin was decreased and the 
relaxation time constant τ was increased in the DOX-HF 
(Table 1). 
 
 
Table 1. Hemodynamic data of rabbits from the control and 
doxorubicin-induced heart failure (DOX-HF) groups. 
 
 
Control 
group 
(n=6) 
DOX-HF group
(n=9) 
 LVSP, mmHg 64.8±4.7 47.7±9.7* 
 LVEDP, mmHg 1.2±0.3 2.28±0.34* 
 dP/dtmax, mmHg/s 3026.0±244.0 1274±266.0* 
 dP/dtmin, mmHg/s -2004.0±378.0 -992.0±171.0* 
 LVPISO, mmHg 148.9±9.2 84.6±13.5* 
τ, ms 36.6±7.7 68.9±7.1* 
 
Values are mean ± S.E.M. LVEDP and LVSP, left ventricular end-
diastolic and systolic pressures, respectively; dP/dtmax and 
dP/dtmin, peak rates of ventricular pressure rise and fall, 
respectively; LVPISO, peak systolic isovolumetric pressure; τ, time 
constant of isovolumetric relaxation. *P<0.05 vs. Control group. 
 
 
Furthermore, the echocardiographic evaluation 
in the DOX-HF group demonstrated a progressive 
increase of the end-diastolic (from 14.2±0.3 to 15.2±0.3 
mm) and end-systolic (from 9.9±0.2 to 11.1±0.3 mm) 
short-axis diameters and a reduction in fractional 
shortening (from 32±1 to 26±1 %) and ejection fraction 
(from 64±1 to 56±2 %) of the left ventricle. This was 
consistent with the presence of dilated cardiomyopathy 
and HF. None of the other parameters measured changed 
significantly after doxorubicin treatment, namely heart 
rate (158±6 vs. 144±7 bpm), left wall thickness in 
diastole (2.26±0.07 vs. 2.20±0.05 mm) and left wall 
thickness in systole (3.40±0.13 vs. 3.42±0.11 mm). 
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Table 2. Mean values of the baseline contractile parameters in 
papillary muscle from the control and doxorubicin-induced heart 
failure (DOX-HF) groups. 
 
Control group 
Contractile 
parameter With EE 
(n=32) 
Without EE 
(n=9) 
DOX-HF 
group 
(n=15) 
AT 
(mN/mm2) 
23.3 ±2.7 17.4 ±1.9* 26.3±4.3 
dT/dtmax 
(mN/mm2/s) 
163.5±17.1 112.5±11.6* 164.5±21.3 
dT/dtmin 
(mN/mm2/s) 
–133.1±15.3 –95.2±9.6* –137.8±22.2 
PS 
(% of Lmax) 
12.0±0.1 9.0±0.1* 11.0±0.1 
dL/dtmax 
(Lmax/s) 
0.89±0.1 0.61±0.06* 0.71±0.05 
dL/dtmin 
(Lmax/s) 
–3.20±0.40 –2.01±0.2* –2.43±0.2 
 
Values are means ± S.E.M. EE, endocardial endothelium; AT, 
active tension; dT/dtmax, maximum velocity of tension rise; 
dT/dtmin, maximum velocity of tension decline; PS, peak isotonic 
shortening; dL/dtmax, maximum velocity of shortening; dL/dtmin, 
maximum velocity of lengthening. * P<0.05 vs. control group 
with intact EE. 
 
Papillary muscle studies 
Mean values of the baseline contractile 
parameters in papillary muscles from the control group 
with intact EE (n=32) and from the DOX-HF group 
(n=15) are shown in Table 2. Removal of the EE (n=9) 
resulted in a negative inotropic effect. Although baseline 
performance of rabbit papillary muscles was similar in 
the control group with intact EE and in the DOX-HF 
group, the contractility of papillary muscles from the 
control group did not significantly decline with increasing 
stimulation frequency, between 1 Hz and 4 Hz, while the 
papillary muscles from the DOX-HF rabbits showed a 
significant decrease in contractility over the same range 
of stimulation frequencies, indicating contractile 
dysfunction and reduced contractile reserve (Fig. 1). In 
the presence of an intact EE, ET-1 promoted 
concentration-dependent positive inotropic and lusitropic 
effects: AT increased by 15.3±5.4 %, 47.2±9.8 % and 
88.6±18.3 %; dT/dtmax, 15.4±5.9 %, 47.1±12.3 % and 
103.7±21.5 %; and dT/dtmin, 13.3±4.9 %, 42.4±6.8 % and 
85.6±16.9 % (at 0.1, 1 and 10 nM, respectively). These 
effects were maintained after damaging the EE, in the 
presence of L-NNA or INDO and in the DOX-HF Group 
(Fig. 2). 
Concerning the effects of ET-1 on myocardial 
distensibility, we found that RT significantly decreased 
after an isometric twitch in the presence of ET-1. Such a 
decrease was not significant at baseline and became 
progressively larger with increasing doses of ET-1 in 
muscles with intact EE. In fact, compared with its value 
at the beginning of the twitch (RTbeg), RT at the end of an 
isometric twitch (RTend) decreased 3.2±1.3, 6.0±1.6 and 
8.8±2.7 % in the presence of 0.1, 1 and 10 nM of  
ET-1, respectively (Fig. 3). Such a decrease in RT 
reflects an increase in myocardial distensibility, because 
restoring the value of RT to its initial value results in an 
increase in the resting length of the muscle. However, no 
significant differences between RTend and RTbeg were 
found, when ET-1 was given after damaging the EE or in 
papillary muscles from the DOX-HF group. Similarly, 
ET-1 did not significantly alter myocardial distensibility 
after blocking release of NO or prostaglandins by L-NNA 
or INDO, respectively.  
 
Discussion 
The present study showed that the increase in 
myocardial distensibility induced by ET-1 is absent in 
DOX-HF and is dependent on NO and prostaglandin 
release.  
The progression of cardiac dysfunction was 
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Fig. 1. Contractile response of rabbit papillary muscles from the 
control group (n=8) and from the doxorubicin-induced heart 
failure (DOX-HF) group (n=7) to steady increases in stimulation 
frequency. Contractility-frequency relationships were then 
obtained by plotting maximum velocity of tension rise against 
frequency of contraction. Control muscles showed a steady
increase in contractility between 1 Hz and 4 Hz, whereas in the 
DOX-HF group, muscles responded in the opposite way. P<0.05: 
*, vs. baseline; #, vs. control. 
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monitored echocardiographically to estimate 
morphological and functional alterations during the 
development of HF. Hemodynamic studies performed 
one week after the last administration of DOX also 
showed the presence of systolic and diastolic dysfunction 
in DOX-HF animals. In addition, as contractile 
dysfunction in papillary muscles is most often not evident 
from changes in baseline performance of muscles that are 
contracting at low stimulating frequencies, but rather on 
an impaired response to increased frequencies (Endoh 
2004), contractility-frequency relationships were studied. 
We found that although baseline performance of normal 
and DOX-HF muscles was similar, contrary to the 
former, the latter showed decreased contractility to 
increased frequencies, indicating contractile dysfunction 
and a reduced contractile reserve. 
Positive inotropic and lusitropic effects of ET-1 
have been previously described by several authors in 
various experimental preparations, although the 
magnitude of the effects varied among distinct animal 
species (Endoh et al. 1998). Rabbits belong to the most 
sensitive animals to ET-1, which was one of the reasons 
for carrying out the experiments in this species. The 
magnitude of positive inotropic and lusitropic effects 
obtained in the present study is in agreement with 
previously published data on rabbit papillary muscles (Li 
et al. 1991, Leite-Moreira et al. 2003, Leite-Moreira and 
Bras-Silva 2004, Bras-Silva and Leite-Moreira 2006). 
These inotropic and lusitropic effects of ET-1 were 
maintained after damaging EE, blocking NO and 
prostaglandins release and in the DOX-HF group. 
Previous studies in vivo and in vitro showed that the 
contractile effects of ET-1 were increased (Li and 
Rouleau 1996), attenuated (Möllmann et al. 2006), 
maintained (Bras-Silva and Leite-Moreira 2006) or even 
reversed (Kelso et al. 1996, Thomas et al. 1996, 
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Fig. 2. Concentration-response curves for the effect of ET-1 on 
the contractile parameters of rabbit papillary muscles in various
experimental conditions: Control group with intact endocardial
endothelium (EE; full circles, n=9); Control group with damaged
EE (open circles, n=9); Control group with intact EE and in the
presence of NG-nitro-L-arginine (L-NNA, open triangles, n=8);
Control group with intact EE and in the presence of Indomethacin
(INDO, full squares, n=7) and doxorubicin-induced heart failure
group (DOX-HF; full triangles, n=8). AT, active tension; dT/dtmax, 
maximum velocity of tension rise; dT/dtmin, maximum velocity of
tension decline. Mean ±S.E.M.; percentage of baseline. * P<0.05
vs. baseline. 
 
 
Fig. 3. Concentration-response curves for the effect of ET-1 on 
resting tension (RT) of rabbit papillary muscles in various 
experimental conditions: Control group with intact endocardial 
endothelium (EE; full circles, n=9); Control group with damaged 
EE (open circles, n=9); Control group with intact EE and in the 
presence of NG-nitro-L-arginine (L-NNA, open triangles, n=8) 
Control group with intact EE and in the presence of indomethacin 
(INDO, full squares, n=7) and doxorubicin-induced heart failure 
group (DOX-HF; full triangles, n=8). Mean ±S.E.M.; percentage 
of baseline. * P<0.05 vs. baseline. 
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MacCarthy et al. 2000) in the presence of HF. This 
difference could be explained by the different 
methodological approaches, different animal species and 
various experimental models of HF. 
In the present study, we therefore observed that 
despite the occurrence of baseline contractile dysfunction 
in failing hearts, baseline performance of papillary 
muscles was similar in control and doxorubicin-treated 
animals. Furthermore, these muscles exhibited the same 
inotropic and lusitropic response to ET-1, but a distinct 
inotropic response to increasing stimulation rates, closer 
to the physiological range. The negative force-frequency 
relationship is a well-known feature of the failing 
myocardium that can be at least partially attributed to 
disturbed calcium homeostasis and energy imbalance 
(Endoh 2004). On the other hand, the contractile response 
to ET-1 involves distinct cellular mechanisms, which 
might explain its similar effects in the normal and failing 
myocardium. Furthermore, ET-1 has the ability to 
increase cardiac contractile efficiency by lowering 
ATPase activity (McClellan et al. 1996) and oxygen 
consumption (Takeuchi et al. 2001) and was considered 
essential for the contractile efficiency of the failing 
myocardium (Sakai et al. 1996). 
With regard to the effects of ET-1 on the 
diastolic properties of the myocardium, we found that the 
decrease in resting tension (increase in myocardial 
distensibility) observed after an afterloaded twitch in the 
presence of ET-1 was not present in the failing 
myocardium. We also confirmed that damaging the EE 
also blocked this effect confirming our previous 
observations (Bras-Silva and Leite-Moreira 2006). In 
previous studies we have also shown that this effect of 
ET-1 on myocardial distensibility was mediated by ETA 
receptor stimulation (Leite-Moreira et al. 2003), and 
dependent on endothelial ETB1 receptor activity, even if 
the direct stimulation of either endothelial ETB1 or 
myocardial ETB2 receptors did not elicit any effect on this 
parameter (Bras-Silva and Leite-Moreira 2006). If we 
take into account that endocardial endothelium is 
dysfunctional in the DOX-HF model (Bras-Silva et al. 
2006) and that the acute effects of ET-1 on myocardial 
distensibility are blocked when the EE is damaged, it 
seems plausible that the blunted effects of ET-1 on 
myocardial distensibility in the failing myocardium could 
be explained by EE dysfunction.  
Once NO and prostaglandins are two of the most 
important endothelial mediators and they are known to be 
released by the endothelium in response to ETB1 receptor 
stimulation (de Nucci et al. 1988, Thiemermann et al. 
1989, Filep et al. 1991, Hirata et al. 1993 Leite-Moreira 
and Bras-Silva 2004), which also influences ET-1 effect 
on myocardial distensibility (Bras-Silva and Leite-
Moreira 2006), we investigated how these two agents 
modulate the ET-1 effects. We found that similarly to 
what happened after damaging EE, after blocking of NO 
or prostaglandin release the ET-1-induced decrease in 
resting tension (increase in distensibility) was not 
observed. 
NO has been shown to increase diastolic 
distensibility (Paulus and Shah 1999, Paulus et al. 1994). 
This effect seems to be mediated by reduction of 
myofilamentary calcium sensitivity because of 
phosphorylation of troponin I by cGMP-dependent 
protein kinase (Shah and MacCarthy 2000). Direct 
myocardial actions of prostaglandins are still not clear. 
With regard to inotropy both negative (Schor and 
Hohlfeld 1992) and positive (Mohan et al. 1995) effects 
were shown in isolated papillary muscles. Regarding 
lusitropy prostaglandins were recently shown to preserve 
early active diastolic relaxation (Kisch-Wedel et al. 2005) 
and to modulate the premature onset of tension decline 
promoted by ghrelin (Soares et al. 2006). These two 
agents, NO and prostaglandins, have also been implicated 
in the negative inotropic effects resulting from selective 
ETB1 receptor stimulation (Leite-Moreira and Bras-Silva 
2004). It seems that independently of the direct actions of 
each of these endothelial agents, they are able to regulate 
both systolic and diastolic effects of ET-1.  
Concerning the pathophysiological relevance of 
our findings, we must point out that a lower resting 
tension of the cardiac muscle indicates the ventricle can 
reach higher filling volumes at lower filling pressures, 
which is undoubtedly quite a powerful adaptation 
mechanism. These acute beneficial ET-1 effects on 
diastolic function seem to be overcome by its role in 
progression to cardiac fibrosis and ventricular remodeling 
when its levels remain chronically elevated (Brunner et 
al. 2006). Additionally, the results of the present study 
emphasize that humoral influences on diastolic cardiac 
function are modulated by the interaction with 
endocardial endothelial mediators, such as NO and 
prostaglandins, which being altered in the failing heart 
might provide new elements for the comprehension of the 
pathophysiology of HF. Finally, doxorubicin is an 
antineoplastic antibiotic widely used in the treatment of a 
variety of cancers, and its clinical use is limited as the 
result of a severe, dose-dependent cardiotoxicity (Monnet 
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and Chachques 2005). In this context, our findings might 
also be relevant to a better understanding of the 
pathophysiology of DOX-induced cardiomyopathy, so 
that efficient protective and/or therapeutic strategies can 
be developed in patients treated with this 
chemotherapeutic agent. 
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